GeneMatrix Gets CE-IVD Mark for NeoPlex STI-7 PLUS, Following STI-7 > News

본문 바로가기
Search

News 목록

Media Reports | GeneMatrix Gets CE-IVD Mark for NeoPlex STI-7 PLUS, Following STI-7

페이지 정보

작성자 Admin 작성일17-11-22 조회878회 댓글0건

본문

GeneMatrix, specialized in multiplex molecular diagnostics, announced today that it received CE-IVD marking for its NeoPlex STI-7 Plus, following NeoPlex STI-7.


The company said, "NeoPlex STI-7 Plus can simultaneously detect seven pathogens that cause bacterial vaginosis, Candida vaginitis, genital herpes, ductal hypersensitivity, and syphilis with a single reaction. In particular, NeoPlex STI-7 PLUS can also detect Group B Streptococcus (GBS), which is recommended to be tested in the last month of pregnancy to prevent neonatal sepsis, so we expect a high demand for pregnant women."


Dr. Soo-Ok Kim, CEO of GeneMatrix, said "With this CE marking, our proprietary NeoPlex multiplex STI diagnostic panel has been expanded to 14 pathogens. We will continue to meet the clinical and diagnoistic needs and will accelerate the launch of NeoPlex products in Europe."

댓글목록

등록된 댓글이 없습니다.


Copyright 2018 © Genematrix Inc., All rights reserved.

Copyrights 2018 ⓒ Genematrix. co.ltd., All rights reserved.